News | May 13, 2021
COVAXIN phase II/III clinical trial approved for 2-18 years
BBIL had proposed to carry out Phase II/III clinical trial of Covaxin in the age group of 2 to 18 years
BBIL had proposed to carry out Phase II/III clinical trial of Covaxin in the age group of 2 to 18 years
The agreement will help ensure wider reach and access to patients in India
The additional allocation of Tocilizumab will ensure sufficient availability for COVID-19 patients and augment the government’s efforts to fight the pandemic
Baricitinib was issued a restricted emergency use approval by the Central Drugs Standard Control Organization (CDSCO)
The drug accumulates in the virus infected cells and prevents virus growth by stopping viral synthesis and energy production
State governments and UTs have been asked to monitor proper distribution within the state/UT covering government and private hospitals
Baricitinib is used in combination with remdesivir for the treatment of suspected or laboratory confirmed COVID-19
Baricitinib is an oral medication that was earlier registered in India for the treatment of moderate to severe active rheumatoid arthritis in adult patients.
This Emergency Use Authorisation will now enable Roche to import the globally manufactured product batches to India
Dorzolamide Hydrochloride and Timolol Maleate Ophthalmic Solution USP, 2% and 0.5% has an estimated market size of US $80 million for twelve months ending December 2020 according to IQVIA
Subscribe To Our Newsletter & Stay Updated
